Although a higher PD-L1 expression is demonstrated to correlate with a higher response rate in patients treated with pembrolizumab [7,8,10,11], the association between clinical outcomes of ICIs and PD-L1 expression levels in NSCLC patients with a high PD-L1 expression has not been extensively investigated. The gene discussed is CD274; the disease is non-small cell lung carcinoma.